Trifluoperazine Hydrochloride
Trifluoperazine Hydrochloride is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Trifluoperazine Hydrochloride; Generic name: TRIFLUOPERAZINE HYDROCHLORIDE; Manufacturer: REMEDYREPACK INC..
| Brand name | Trifluoperazine Hydrochloride |
|---|---|
| Generic name | TRIFLUOPERAZINE HYDROCHLORIDE |
| Manufacturer | REMEDYREPACK INC. |
| Used for | INDICATIONS AND USAGE For the management of schizophrenia. Trifluoperazine HCl is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine HCl is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). When used in the treatment of non-psychotic anxiety, trifluoperazine HCl should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine HCl at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irrever |
| Dosage | DOSAGE AND ADMINISTRATION Adults Dosage should be adjusted to the needs of the individual. The lowest effective dosage should always be used. Dosage should be increased more gradually in debilitated or emaciated patients. When maximum response is achieved, dosage may be reduced gradually to a maintenance level. Because of the inherent long action of the drug, patients may be controlled on convenient b.i.d. administration; some patients may be maintained on once-a-day administration. When trifluo |
| Warnings | WARNINGS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Trifluoperazine hydrochloride is not approved for the treatment of patients with dementia-related psychosis (see BOXED WARNING ). Tardive Dyskinesia Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may develop in patients treated with neurolepti |
| Active ingredient(s) | TRIFLUOPERAZINE HYDROCHLORIDE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=069d3469-138b-4e4f-a7bb-6acac5f86abb |